Finally, the accumulation of ROS due to GPx2 knockdown via the KYNU kyn-AhR regulatory pathway could suppress GC progression and metastasis, which provided evidence supporting the role of GPx2 in GC progression and recognized it as a therapeutic target and novel potential prognostic marker for GC [55]. Here, GPX2 is linked to gastric cancer.